|
|
Article: Inflazyme to Acquire Adprotech Limited; Gains New Inflammation Research Technology and Clinical Program.
- Article from:
- Business Wire
- Article date:
- April 7, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
VANCOUVER, British Columbia & CAMBRIDGE, England--(BUSINESS WIRE)--April 7, 2004--Inflazyme Pharmaceuticals Ltd. (TSX: IZP) and Adprotech Ltd., a private U.K. based company, today announced that they have entered into an agreement whereby, subject to necessary regulatory approvals, Inflazyme will acquire Adprotech. Inflazyme will issue approximately 12.7 million common shares to acquire all outstanding Adprotech shares in a deal valued at approximately CDN$20 million (see below).
The acquisition will give Inflazyme a new inflammation technology platform, complement inhibition, and a potential novel clinical ...